In the present study, we aimed to identify new biomarkers of IFNβ bioactivity in order to compare their specificities as genes induced by type I IFNs with the MxA, and evaluate their potential implication in MS pathogenesis. The gene discussed is MX1; the disease is myeloid sarcoma.